不可切除胰腺癌患者肿瘤出血的姑息性放疗:一项单中心回顾性研究
本研究回顾性分析了2013年5月至2022年1月单中心不可切除胰腺癌患者中经内镜确诊肿瘤出血并接受姑息性放疗的20例患者,止血率70%,无3级及以上不良事件,中位止血时间8.5天,再出血率21.4%,中位总生存52天,作者认为姑息性放疗是有效且安全的治疗方式。
要点
- 20例接受姑息性放疗的肿瘤出血患者中14例(70%)止血成功,无3级及以上不良事件。
- 中位止血时间8.5天(范围7-14天),再出血率21.4%(3/14)。
- 止血后14例中7例(50%)可开始或恢复化疗,其中位总生存260天(95%CI 76-未评估)。
核心结论
- 作者认为姑息性放疗是不可切除胰腺癌患者肿瘤出血的有效且安全的治疗方式。
研究设计与样本
- 单中心回顾性研究,回顾2013年5月至2022年1月本机构诊断的不可切除胰腺癌患者病历,筛选内镜确诊肿瘤出血并接受姑息性放疗的患者。
- 姑息性放疗总剂量为30 Gy分10次、20 Gy分5次或8 Gy单次,剂量选择由主治放射肿瘤科医生决定。
主要发现
- 研究期间本院诊断不可切除胰腺癌2562例,其中225例(8.8%)发生消化道出血,225例中63例(2.5%)诊断为肿瘤出血,20例(0.8%)接受姑息性放疗。
- 20例接受姑息性放疗的患者中14例(70%)止血成功,无一例发生与姑息性放疗相关的3级及以上不良事件,中位止血时间8.5天(范围7-14天),再出血率21.4%(3/14)。
- 姑息性放疗后中位血红蛋白从5.9 g/dL显著升高至9.1 g/dL(p < 0.001),中位红细胞输血量从1120 mL(范围280-3360 mL)有下降趋势至280 mL(范围0-5560 mL)(p = 0.052)。
- 中位总生存52天(95%CI 39-317);14例止血成功者中7例(50%)可开始或恢复化疗,其中位总生存260天(95%CI 76-未评估)。
- 3例再出血分别发生在姑息性放疗开始后第16、22和25天。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with unresectable pancreatic cancer (PC) sometimes experience gastrointestinal bleeding (GIB) due to tumor invasion of the gastrointestinal tract (tumor bleeding); no standard treatment has been established yet for this complication. Palliative radiotherapy (PRT) could be promising, however, there are few reports of PRT for tumor bleeding in patients with unresectable PC. Therefore, we evaluated the outcomes of PRT for tumor bleeding in patients with unresectable PC. METHODS: We reviewed the medical records of patients with unresectable PC diagnosed at our institution between May 2013 and January 2022, and identified patients with endoscopically confirmed tumor bleeding who had received PRT. PRT was administered at a total dose of 30 Grays (Gy) in 10 fractions, 20 Gy in 5 fractions, or 8 Gy in a single fraction, and the dose selection was left to the discretion of the attending radiation oncologists. RESULTS: During the study period, 2562 patients were diagnosed as having unresectable PC at our hospital, of which 225 (8.8%) developed GIB. Among the 225 patients, 63 (2.5%) were diagnosed as having tumor bleeding and 20 (0.8%) received PRT. Hemostasis was achieved in 14 of the 20 patients (70%) who received PRT, and none of these patients developed grade 3 or more adverse events related to the PRT. The median time to hemostasis was 8.5 days (range 7-14 days). The rebleeding rate was 21.4% (3/14). The median hemoglobin level increased significantly (p < 0.001) from 5.9 to 9.1 g/dL, and the median volume of red blood cell transfusion tended (p = 0.052) to decrease, from 1120 mL (range 280-3360 mL) to 280 mL (range 0-5560 mL) following the PRT. The median overall survival (OS) was 52 days (95% confidence interval [CI] 39-317). Of the 14 patients in whom hemostasis was achieved following PRT, chemotherapy could be started/resumed in seven patients (50%), and the median OS in these patients was 260 days (95% CI 76-not evaluable [NE]). Three patients experienced rebleeding (21.4%), on days 16, 22, and 25, after the start of PRT. CONCLUSION: This study showed that PRT is an effective and safe treatment modality for tumor bleeding in patients with unresectable PC.
引用
- Shibuki T, Sasaki M, Yamaguchi S, et al. Palliative radiotherapy for tumor bleeding in patients with unresectable pancreatic cancer: a single-center retrospective study. Radiat Oncol. 2023. PMID: 37907912. doi:10.1186/s13014-023-02367-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。